Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · TG Therapeutics (TGTX)

TG Therapeutics shareholders approve increase in authorized common shares to 190 million

Mixed Impact 3 of 5 shareholder Written later

At its June 14, 2024 annual meeting, TG Therapeutics stockholders approved raising authorized common stock from 175,000,000 to 190,000,000 shares and removing the full-value awards limit in the 2022 Incentive Plan. The company filed the charter amendment the same day, and all five proposals passed, although three director nominees received less than half of the votes cast for them. The larger share authorization gives the company room to issue more common stock, which could dilute existing holders.

Key points

  • Authorized common shares rise from 175,000,000 to 190,000,000; 73,780,225 votes for, 36,348,764 against, 946,040 abstentions.
  • 2022 Incentive Plan amendment removing the full-value awards limit passed with 66,744,142 votes for and 8,625,685 against.
  • Advisory say-on-pay vote: 42,346,581 for, 31,019,084 against, 2,748,761 abstentions.
  • Yann Echelard (46.05%), Daniel Hume (46.03%) and Sagar Lonial, MD (43.75%) each received less than half of votes cast for them.

The filing

CompanyTG Therapeutics (TGTX)
Form8-K, current report
Filed with the SECJun 17, 2024, 4:48 PM ET
Accession number0001437749-24-020510

Items reported: 5.02 Director / Officer Change5.03 Bylaw / Charter Amendment5.07 Shareholder Vote Results

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 17, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.